Company intelligence / Profile preview

Inflection Biosciences

Dublin / Blackrock, Dublin, Irelandinflectionbio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Inflection Biosciences is developing first-in-class small molecule inhibitors targeting PIM kinase and PI3K pathways for oncology and immunology indications. Lead asset IBL‑202 has shown preclinical efficacy in aggressive B-cell malignancies and T-cell lymphoma, with published data in peer-reviewed journals. The company’s pipeline includes both wholly owned and partnered programs, with some assets licensed out for further development.

Therapeutic areas: OncologyImmunology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

3 assets

IBL-202

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

AUM Biosciences (AUM302/IBL‑302 partnership)Mysthera Therapeutics (licensee of PIM kinase inhibitors)

Beyond the preview

Go deeper on Inflection Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inflection Biosciences.

Explore the full profile